SCHEMBL1629002

SCHEMBL1629002

CNC(=O)c1cc(-c2ccnn2-c2ccccc2Cl)c(O)cc1O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.53
NR3C2 P08235 2/20 0.47
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
MAPK14 Q16539 1/20 0.39
RIPK1 Q13546 1/20 0.39
PDE11A Q9HCR9 1/20 0.38
ELANE P08246 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
NTRK1 P04629 1/20 0.35
TP53 P04637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629007 0.88 HSP90AA1 (0.53) HSP90AA1NR3C2JAK2JAK1TYK2
SCHEMBL1628854 0.87 HSP90AA1 (0.51) HSP90AA1NR3C2JAK2JAK1TYK2
SCHEMBL1629132 0.84 HSP90AA1 (0.56) HSP90AA1NR3C2JAK2JAK1TYK2
SCHEMBL1630247 0.81 HSP90AA1 (0.56) HSP90AA1NR3C2PDE11AL3MBTL1
SCHEMBL15049727 0.80 HSP90AA1 (0.53) HSP90AA1NR3C2JAK2JAK1TYK2
SCHEMBL1628864 0.79 HSP90AA1 (0.69) HSP90AA1NR3C2PDE11A
SCHEMBL2076846 0.78 HSP90AA1 (0.61) HSP90AA1NR3C2PDE11AMEN1KMT2A
SCHEMBL1219136 0.78 HSP90AA1 (0.61) HSP90AA1
SCHEMBL1219220 0.78 HSP90AA1 (0.53) HSP90AA1NR3C2MAPK14PDE11AKMT2A
SCHEMBL1219601 0.78 HSP90AA1 (0.56) HSP90AA1NR3C2PDE11A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP claimed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US claimed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US claimed
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP disclosed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US disclosed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085904-A1 1,5-Diphenylpyrazoles HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885NR3C2 558/4885JAK2 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.